Featured Clinical Focus

AML Biomarker-Driven Lung Cancer Breast Cancer CAR T-Cell Therapy Chronic Lymphocytic Leukemia EGFR+ Lung Cancer Follicular Lymphoma GI Cancers HCC HER2-Positive Breast Cancer Lung Cancer Lymphomas Mantle Cell Lymphoma MPNs Multiple Myeloma Prostate Cancer Renal Cell Carcinoma Thyroid Cancers

Brain Cancer Breast Cancer Gastrointestinal Cancer Genitourinary Cancers Gynecologic Cancers Head & Neck Cancers Hematology Leukemias Lung Cancer Lymphomas Melanoma Sarcoma Skin Cancers Thyroid Cancers

All Videos Case-Based Peer Perspectives Expert Perspective Virtual Tumor Board Interviews Investigator Perspectives Medical World News Podcasts Precision Medicine

All Publications CBPP Spotlight Live Evolving Paradigms Targeted Therapies in Oncology

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
Do Not Sell My Information
Privacy
Terms & Conditions

© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Featured Clinical Focus

AML
Biomarker-Driven Lung Cancer
Breast Cancer
CAR T-Cell Therapy
Chronic Lymphocytic Leukemia
EGFR+ Lung Cancer
Follicular Lymphoma
GI Cancers
HCC
HER2-Positive Breast Cancer
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
MPNs
Multiple Myeloma
Prostate Cancer
Renal Cell Carcinoma
Thyroid Cancers

Clinical FocusSee All >

Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Cancers
Head & Neck Cancers
Hematology
Leukemias
Lung Cancer
Lymphomas
Melanoma
Sarcoma
Skin Cancers
Thyroid Cancers

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
Do Not Sell My Information
Privacy
Terms & Conditions

© 2021 MJH Life Sciences^™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Mechanism of Action: Sorafenib

May 21, 2013

Sorafenib is small molecule inhibitor approved for the treatment of primary kidney cancer and advanced primary liver cancer.